 |
 |
 |
 |
 |
|
||
 |
|
||
 |
|
||
 |
|
||
 |
|
||
| |
REFERENCES
1 Clinical Pharmacology 2000. Gold Standard Multimedia.
2. Gatti D, Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging. 1999 Oct;15(4):285-96.
3.Glazier MG, Bowman MA. A Review of the Evidence for the Use of Phytoestrogens as a Replacement for Traditional Estrogen Replacement Therapy. Arch Intern Med. 2001;161(9):1161-1172.
4. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcif Tissue Int. 1997;61 Suppl 1:S23-7.
5. Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, Gennari C, Reginster JY. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA. 2001 Mar 21;285(11):1482-8
6. Lissett CA, Shalet SM.. Effects of growth hormone on bone and muscle. Growth Horm IGF Res. 2000 Apr;10 Suppl B:S95-101.
7. Bell NH, Termine JD. Treatment and prevention of osteoporosis: future directions. J S C Med Assoc. 2001 Mar;97(3):99-101
8. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-1441.
9. Hennessy S, Strom BL. Statins and fracture risk. JAMA. 2001 Apr 11;285(14):1888-9.
10. Kamel HK, Perry HM 3rd, Morley JE. Hormone replacement therapy and fractures in older adults. J Am Geriatr Soc. 2001 Feb;49(2):179-87.
11. Iqbal MM. Osteoporosis: epidemiology, diagnosis, and treatment. South Med J. 2000 Jan;93(1):2-18.
12. Ederveen AG, Kloosterboer HJ. Tibolone, a steroid with a tissue-specific hormonal profile, completely prevents ovariectomy-induced bone loss in sexually mature rats. J Bone Miner Res. 1999 Nov;14(11):1963-70.
13. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab. 1999 Sep;84(9):3076-81.
14. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000 Feb;85(2):720-6.
15. Lopez FJ. New approaches to the treatment of osteoporosis. Curr Opin Chem Biol. 2000 Aug;4(4):383-93.
return
to top of page